Health Library / Hormones
This content is for education only and is not medical advice. I'm a fitness coach, not a physician. Talk to your doctor before starting any medication, hormone, supplement, or new exercise program, especially if you have a medical condition or take prescriptions.
Walk into a longevity clinic in Austin, Scottsdale or Miami and you'll get handed a menu with words on it nobody has ever explained to you. BPC-157. CJC-1295. Ipamorelin. GHK-Cu. Semax. The Wolverine Cocktail, which is a real thing they will genuinely offer to sell you.
Most people nod, pick something, and never find out what any of it was. So let's fix that, because you can't make a good decision about something you can't define.
A peptide is a short chain of amino acids. That's the entire definition. Long chains are proteins; short chains are peptides, and the line between them is roughly arbitrary.
So "peptide" is a size category, not a drug class. Having an opinion about peptides is like having an opinion about molecules. Your body makes thousands of them and they do wildly different jobs — insulin is a peptide. So is the signal that tells you you're full. So is semaglutide, the GLP-1 drug in its own module.
This matters because the marketing uses the word as if it means one thing, usually something natural and gentle. It doesn't mean anything on its own. What matters is which specific peptide, what it does, and what's actually been shown about it.
BPC-157 is the famous one. "Body Protection Compound," a fragment of a protein found in gastric juice. It's sold for tissue repair, joint and tendon recovery, and gut health, and it's the reason people started calling this stuff Wolverine. The Wolverine Cocktail pairs it with TB-500.
TB-500 / thymosin beta-4 — tissue repair and collagen, usually sold alongside BPC-157 for the same purposes.
CJC-1295 and ipamorelin are growth hormone secretagogues. Rather than giving you growth hormone, they prompt your pituitary to release more of your own, in pulses that roughly follow your natural rhythm. Sermorelin is the older cousin. This category is the closest thing to the HGH pitch that doesn't involve HGH, and it's marketed for body composition, recovery and sleep.
GHK-Cu is a copper-binding peptide that shows up both as an injectable and as an ingredient in serious skincare. Claimed for healing, skin quality and cellular renewal.
Semax and Selank came out of Russian research and are sold as nootropics — cognition, mood, stress resilience. Usually nasal.
Epitalon is a pineal-gland peptide with telomere-lengthening claims attached. This one leans hardest on very old Russian research and very little else.
SS-31 and MOTS-c target mitochondria — cellular energy production.
KPV is marketed as an anti-inflammatory, often for gut issues.
PT-141 (bremelanotide) is worth separating out, because it is genuinely
FDA-approved — sold as Vyleesi for low sexual desire in premenopausal women. Same with tesamorelin, approved as Egrifta for a specific HIV-related condition. Those two are approved medicines that happen to be peptides, which is a different category from the compounded ones.
Almost all of the injectable ones are subcutaneous — a small needle into the fat of the abdomen, the kind of injection diabetics have done at home for a century. Some are nasal sprays. GHK-Cu turns up topically. A few are oral, though absorption through the gut is the hard problem with peptides generally and most don't survive it.
The route in is usually a consult — increasingly telehealth — followed by a compounded prescription shipped to your door, with the clinic checking in periodically. Austin clinics like Texas Center Wellness describe a four-step loop: evaluation and biomarkers, a customized protocol, treatment, then ongoing adjustment. That's the standard shape across the industry.
Who's using them: professional and college athletes, largely for recovery, and often quietly. Longevity clinics, as the mid-tier offering between supplements and hormones. The biohacking scene, where stacking several at once is normal and documented in enormous detail on forums. And increasingly ordinary people in their forties and fifties who found a telehealth clinic and are trying to fix a shoulder that hasn't been right in two years.
Here's the part that surprises people, and I'd rather tell you than have you find out after six months of injections.
For BPC-157 — the single most popular peptide in this entire category — there are essentially no published randomized controlled trials in humans. Not "the evidence is mixed." The human trials largely haven't been done. What exists is a substantial body of rodent research, much of it from one research group, showing genuinely interesting tendon, gut and wound healing effects in animals, plus an enormous volume of personal reports from people who took it and felt better.
That's not nothing. Rat data plus thousands of consistent anecdotes is a reasonable reason to run a trial. It is not the same as knowing it works in humans, and anybody telling you it's proven is describing research that doesn't exist.
The growth hormone secretagogues have more human data behind them, because they've been studied as drugs — they do measurably raise growth hormone and IGF-1. Whether that translates into the outcomes people want at 55, over years, is much less established.
Semax and Selank have a Russian clinical literature that's hard to evaluate from here — different standards, limited translation, little replication in the West.
Epitalon's evidence is thin and old.
So the honest summary for most of this category: plausible mechanisms, promising animal work, thin human data, and a lot of people who swear by it. Which is exactly what an emerging field looks like before anyone knows the answer.
This is where the ground shifts, and if you read something written two years ago it's probably wrong.
In 2023 the FDA placed BPC-157 in Category 2 of the 503A bulks list — substances flagged for potential significant safety risk, which meant compounding pharmacies could no longer legally prepare it. A number of other popular peptides went the same way. That's why clinics abruptly stopped offering things in 2023 and 2024.
Then in April 2026 the FDA removed BPC-157 and eleven other peptides from Category 2 entirely, moving them back into evaluation. In July 2026 the agency's Pharmacy Compounding Advisory Committee voted in favor of six of seven peptides under review for potential inclusion on the 503A list, which would formally permit compounding under defined conditions.
Read that carefully, because clinics are already spinning it: coming off a restricted list is not the same as being approved. It means the question is open again. The specific status of any given peptide right now is something worth checking rather than assuming, and it's why we re-verify this module before every release that touches it.
Growth hormone itself sits in a category nothing else here occupies.
Congress wrote a specific provision into federal law making distribution of hGH for anything outside a narrow set of diagnosed conditions a criminal matter. Not off-label, not a gray area — carved out on purpose. Anti-aging, athletic performance and body composition are not on the approved list, and there's no version of this where a clinic has found a clever way around it.
Legitimate uses exist and those patients are real. It's just a genuinely different legal object from everything else on the menu, and that's the thing almost nobody knows.
The original 1990 study that launched the whole industry did find older men gained lean mass and lost fat on growth hormone. What followed was less flattering: the functional benefits didn't track the body composition changes, and side effects showed up reliably — fluid retention, joint pain, carpal tunnel, effects on blood sugar.
Peptides are not steroids and they will not act like them. Nothing in this category builds significant muscle on its own. The secretagogues nudge a hormone your body already makes; they don't override the ceiling on it.
And none of it substitutes for the boring inputs. A peptide protocol layered on five hours of sleep and 60 grams of protein a day is an expensive way to stay where you are.
Know which specific compound you're being offered and what's actually known about that one — not about "peptides." Ask whether it's FDA-approved, and if not, where it's being compounded and what the pharmacy's status is. Ask what the clinic expects to change and how you'd both know. And tell whoever manages your health that you're doing it, because it belongs in your chart.
This is a field where the science is real, the human evidence is thinner than the marketing, and the rules are actively being rewritten. All three of those can be true at once, and knowing that is most of what you need.
These are listed for reference, not as recommendations. Ockerman Health has no financial relationship with any provider listed here, receives nothing for these links, and does not endorse, vouch for or verify any of them. They appear because they publicly advertise the services this article explains, so you can see for yourself what's being offered and what it costs. Anything on this list is between you and them — and anything medical is between you and your doctor.
Last updated September 30, 2026